VolitionRx markets oncology portfolio for out-licensing via PharmaVentures

VOLITIONRX LTD

Company engaged PharmaVentures as licensing adviser; document made available to third parties starting September 16, 2024.
Document provides brief introduction to certain components of the oncology portfolio; no specific assets or terms disclosed.
No revenue, deal value, or counterparty announced; no financial impact provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.